Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,038.00. The company’s shares closed yesterday at $868.88.

Devarakonda covers the Healthcare sector, focusing on stocks such as Amgen, Cytokinetics, and Eli Lilly & Co. According to TipRanks, Devarakonda has an average return of 2.8% and a 40.10% success rate on recommended stocks.

In addition to Truist Financial, Eli Lilly & Co also received a Buy from Leerink Partners’s David Risinger in a report issued on February 7. However, on January 28, Cantor Fitzgerald assigned a Hold rating to Eli Lilly & Co (NYSE: LLY).

LLY market cap is currently $833.8B and has a P/E ratio of 74.98.

Based on the recent corporate insider activity of 136 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year. Earlier this month, Lilly Endowment Inc, a Major Shareholder at LLY sold 210,000.00 shares for a total of $183,566,194.35.